Evidence map›Paper›PMID 41476313›Full record

ArticleCell division2025

MiR-124-3p inhibits stomach adenocarcinoma progression by targeting AHR to induce autophagy.

Qian Wan, Siwei Wang, Wei Dong, Xinyi Liu, Xiangyun Li, Chuan Liu, Shanling Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell division, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qian Wan *Critical Care Medicine Department, Sichuan Cancer Hospital, Affiliated Cancer Hospital to University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Wuhou District, Chengdu, 610041, Sichuan, China.
Siwei Wang *Critical Care Medicine Department, Sichuan Cancer Hospital, Affiliated Cancer Hospital to University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Wuhou District, Chengdu, 610041, Sichuan, China.
Wei Dong *Critical Care Medicine Department, Sichuan Cancer Hospital, Affiliated Cancer Hospital to University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Wuhou District, Chengdu, 610041, Sichuan, China.
Xinyi Liu *Critical Care Medicine Department, Sichuan Cancer Hospital, Affiliated Cancer Hospital to University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Wuhou District, Chengdu, 610041, Sichuan, China.
Xiangyun LiKey Laboratory of Hubei Wuhan Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan, China.
Chuan LiuKey Laboratory of Hubei Wuhan Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan, China.
Shanling XuCritical Care Medicine Department, Sichuan Cancer Hospital, Affiliated Cancer Hospital to University of Electronic Science and Technology of China, No. 55, Section 4, Renmin South Road, Wuhou District, Chengdu, 610041, Sichuan, China. xushanling@scszlyy.org.cn.

Funding

Sichuan Province Key Clinical Specialty Construction Project Sichuan Medical Research Project S22037
6 · The paper itself

Abstract

backgroundMicroRNA-124-3p (miR-124-3p) has been widely reported as an important tumor-suppressive regulator in multiple malignancies. Nevertheless, its precise biological function in stomach adenocarcinoma (STAD) remains insufficiently clarified.

methodsWe applied large-scale bioinformatics interrogation of The Cancer Genome Atlas (TCGA) STAD cohort, combined with in vitro cellular assays and in vivo xenograft experiments, to explore both the biological significance and molecular mechanisms of miR-124-3p in STAD progression.

resultsMiR-124-3p expression was significantly downregulated in STAD tissues and correlated with advanced pathological stage, poor prognosis, and reduced survival outcomes. Functional investigations confirmed that miR-124-3p directly interacts with the 3'-UTR of the aryl hydrocarbon receptor (AHR) mRNA, suppressing its expression and inducing autophagy. This regulation led to impaired proliferation, migration, and invasiveness of STAD cells. Restoration of AHR expression reversed these tumor-suppressive effects. Moreover, in vivo delivery of miR-124-3p inhibited tumor growth and mitigated cancer-induced cachexia in nude mice.

conclusionThese findings establish miR-124-3p as a key suppressor of STAD progression via AHR-mediated autophagy, underscoring its promise as both a diagnostic biomarker and a therapeutic candidate.

Indexed as

Aryl hydrocarbon receptorAutophagyBiomarkerMiR-124-3pStomach adenocarcinoma

Identifiers

PMID41476313
PMCPMC12866595

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.